Your privacy, your choice

We use essential cookies to make sure the site can function. We also use optional cookies for advertising, personalisation of content, usage analysis, and social media.

By accepting optional cookies, you consent to the processing of your personal data - including transfers to third parties. Some third parties are outside of the European Economic Area, with varying standards of data protection.

See our privacy policy for more information on the use of your personal data.

for further information and to change your choices.

Skip to main content
Fig. 4 | Harm Reduction Journal

Fig. 4

From: Examining the benefit of a higher maintenance dose of extended-release buprenorphine in opioid-injecting participants treated for opioid use disorder

Fig. 4

Incidence proportion (in %) for TEAEs by injection. Proportion of participants reporting treatment-emergent adverse events (TEAEs) by individual BUP-XR maintenance dose injections (1–6). The denominator (shown at the bottom) was the number of participants receiving that injection, and the numerator was the number of participants reporting TEAE between that injection (including the day of injection) and the next injection

Back to article page